Langley Paul C
Adjunct Professor, College of Pharmacy, University of Minnesota, Minneapolis MN.
Innov Pharm. 2022 Dec 12;13(2). doi: 10.24926/iip.v13i2.4861. eCollection 2022.
Fundamental measurement is the basis for a rational assessment of patient reported outcome (PRO) value claims; both as response to therapy and the submission of credible and evaluable value claims to formulary committees and other health system decision makers. It is important to emphasize the importance of creating interval and ratio scales as opposed to nominal and ordinal scales to support value claims; a recognition that follows from acceptance of conjoint simultaneous measurement and the contribution of Rasch or modern measurement theory (RMT). Failure to appreciate the role of RMT has led thousands of researchers simply to apply numerals to events, inappropriately applying the techniques of classical statistical analysis, with the result that all that is produced are ordinal PRO scores. Instead, we should be aiming for interval and ratio scores based on a comprehensible latent trait and the application of the Rasch model. The purpose of this brief commentary is to review the measurement properties of PRO value claims for mavacamten (Camzyos; Bristol Myers Squibb) in symptomatic hypertrophic cardiomyopathy (SHCM) and to judge whether they have any validity when judged against the requirements of modern measurement theory. The assessment includes both the recent evidence report by the Institute for Clinical and Economic Review (ICER) for mavacamten as well as pivotal randomized trial (RCT) value claims that combine clinical endpoints with PROs that fail the standards of fundamental evidence. These include the Kansas City Cardiomyopathy Questionnaire (KCCQ), the New York Heart Association (NYHA) functional classification and the EuroQuol EQ-5D-5L multiattribute health related quality of life (HRQoL) preference instrument. The review concludes that apart from purely clinical claims based on the various pivotal trials, there are no PRO claims for mavacamten in SHCM that meet the required measurement standards.
基本测量是合理评估患者报告结局(PRO)价值声明的基础;这既关乎对治疗的反应,也涉及向处方委员会及其他卫生系统决策者提交可信且可评估的价值声明。强调创建区间量表和比率量表而非名义量表和顺序量表对于支持价值声明的重要性很有必要;这种认识源于对联合同时测量以及拉施或现代测量理论(RMT)贡献的认可。未能认识到RMT的作用导致数千名研究人员只是简单地给事件赋予数字,不恰当地应用经典统计分析技术,结果所产生的只是顺序PRO分数。相反,我们应该基于可理解的潜在特质和拉施模型的应用来追求区间分数和比率分数。本简短评论的目的是回顾mavacamten(Camzyos;百时美施贵宝公司)在症状性肥厚型心肌病(SHCM)中的PRO价值声明的测量属性,并根据现代测量理论的要求判断它们是否具有任何效度。评估既包括临床与经济评论研究所(ICER)近期关于mavacamten的证据报告,也包括将临床终点与不符合基本证据标准的PRO相结合的关键随机试验(RCT)价值声明。这些声明包括堪萨斯城心肌病问卷(KCCQ)、纽约心脏协会(NYHA)功能分级以及欧洲五维健康量表EQ - 5D - 5L多属性健康相关生活质量(HRQoL)偏好工具。该评论得出结论,除了基于各种关键试验的纯粹临床声明外,SHCM中mavacamten不存在符合所需测量标准的PRO声明。